Pulmonary arterial hypertension (PAH) is a life-threatening, progressive condition that eventually leads to right heart failure. Endothelin receptor antagonists (ETRAs) have been shown to be a safe and efficacious treatment for PAH. Sitaxsentan is a highly selective oral ETRA that, in clinical trials, has demonstrated significant improvements in exercise capacity, functional class and pulmonary hemodynamics in PAH. Sitaxsentan has been shown to be a well tolerated and effective agent with a durable response for the treatment of PAH, and is associated with a low incidence of liver toxicity.
- Endothelin A
- Endothelin receptor antagonist
- Endothelin receptor inhibitor
- Pulmonary hypertension
ASJC Scopus subject areas
- Molecular Medicine
- Cardiology and Cardiovascular Medicine